Find Your Script
MARCH 21, 2022
Studying is a skill…one that we may or may not have mastered during many years of education. I know I went through different study methods before settling on one that worked for me during 7 years of higher education. An important part of successful studying is staying focused. If you also want to improve study habits, see this post on the topic.
pharmaphorum
MARCH 21, 2022
Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation to Exkivity (mobocertinib) as a monotherapy for non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR exon20 insertion mutations, after first-line chemotherapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
MARCH 21, 2022
Over the years, the incidence and prevalence of chronic diseases, have increased significantly. Presently, the recommended treatment options for such clinical conditions are mostly biologics, which need to be administered via parenteral routes to ensure maximum therapeutic benefit. Given the inherent requirement for frequent medication, patients suffering from such long-lasting clinical conditions generally end up spending high amounts on the prescribed therapeutic regimen, and numerous hospital
pharmaphorum
MARCH 21, 2022
The International Virtual Reality Healthcare Association (IVRHA) held its 6th annual conference in Nashville, Tennessee, showcasing medical extended reality (XR) experiences and the companies impacting the healthcare ecosystem. As Adam Elsesser, CEO of Penumbra, stated in his keynote, when many people think of virtual reality, they often think of gaming.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
MARCH 21, 2022
Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery
pharmaphorum
MARCH 21, 2022
Bristol-Myers Squibb is the first big pharma to strike a deal with Volastra Therapeutics, a start-up that has developed a drug discovery platform based on chromosomal instability (CIN), a common but under-investigated feature of solid tumours. BMS is paying $30 million into the collaboration upfront, with a total deal value of $1.1 billion, for programmes addressing up to three undisclosed targets in cancer therapy.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
MARCH 21, 2022
A clinical trial has shown that patients with cardiovascular disease who need cardiac rehabilitation were more likely to take part in a digital programme than face-to-face sessions. The study published in the journal JMIR Cardio found that participation in rehabilitation improved from 21% to 63% when patients were offered an app-based system – Cardihab’s SmartCR – as an alternative.
pharmaphorum
MARCH 21, 2022
In 2015, NICE said that BioMarin’s Vimizim could be used to treat patients with the ultra-rare disease Morquio A syndrome, while real-world data was collected on its efficacy. Now – almost seven years later – it has upgraded the drug to routine NHS use. In the meantime, NICE ha collected clinical data from 69 people treated with Vimizim (elosulfase alfa), which suggests that it is able to slow the progression of Morquio A – also known as mucopolysaccharidosis type 4A.
pharmaphorum
MARCH 21, 2022
Identify, Validate, & Clinically Develop Novel Targets to Modulate Myeloid Cells & Overcome Solid Tumor Barriers. Returning in 2022, the? Tumor Myeloid-Directed Therapeutics Summit ?is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment. This is your ultimate forum to identify, validate, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor func
pharmaphorum
MARCH 21, 2022
Shares in Provention Bio cratered last July when the FDA turned down its marketing application for type 1 diabetes therapy teplizumab. But armed with new data it has tried again, with the FDA due to make a decision on the new filing by 17 August. Provention is seeking approval of teplizumab as a treatment to delay clinical type 1 diabetes in at-risk individuals, hoping the drug can become the first disease-modifying therapy in these patients.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
MARCH 21, 2022
Neuroscience is arguably the next great frontier in medicine and 2022 dawned with a wave of exhilarating progress for the neurodegenerative drug development community. Eli Lilly is investing $700M into genetic medicine, announcing plans to establish a Boston research center, and with the acquisition of Prevail Therapeutics in late 2020, Lilly secured access to two gene therapies that had already advanced into human testing — with one targeting Parkinson’s disease and the other, dementi
pharmaphorum
MARCH 21, 2022
Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy including Merck & Co. The US regulator cleared BMS’ LAG-3 drug relatlimab as a fixed-dose combination with its PD-1 inhibitor Opdivo (nivolumab) – under the Opdualag brand name – in patients aged 12 or over with unresectable or metastatic melanoma.
pharmaphorum
MARCH 21, 2022
The integration of a Clinical Metadata Repository (CMDR) and a Clinical Data Repository (CDR) presents the opportunity to maximize automation across the end-to-end clinical trial lifecycle. It also affords the ability to leverage wider benefits that can’t be achieved through just one solution. But there’s no use in technology partnerships without tangible interoperability in place.
pharmaphorum
MARCH 21, 2022
Although resources exist for digital health entrepreneurs looking to raise their first key investment round, industry advice on next steps is harder to find. The growth of a start-up after obtaining Series A funding is a transformational phase when scaling up the company becomes critical. The CEO can experience pressure to deliver on the revenue growth goals, whilst still developing their product, growing the team, and implementing core processes for the company.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Expert insights. Personalized for you.
130 
Let's personalize your content